Lenacapavir treats and prevents HIV, it does not cure infection | Fact check
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
FOX 5 Atlanta on MSN5d
Injectable HIV preventative lenacapavir touted as breakthrough by Emory experts
A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...
Northcountrypublicradio.org14m
This drug is the 'breakthrough of the year' -- and it could mean the end of the HIV epidemic
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.
AOL9d
Lenacapavir injection lowers HIV risk by 96%
One study revealed that injection of the medication lenacapavir every six months could greatly reduce the risk for HIV ...
Lenacapravir treats and prevents HIV, it does not cure infection | Fact check
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
DPA International on MSN22m
Science journal: HIV protection is 2024 research breakthrough
The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...
FACT CHECK: No, Scientists Did Not Find A New Cure For AIDS That Costs $40K
A post on Facebook claims that a new cure for Acquired immunodeficiency syndrome (AIDS) has been discovered and will cost $40 ...
HIV prophylactic lenacapavir — very safe and very expensive
Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...
Neurology Advisor2d
Incidence of HIV Lower With Twice-Yearly Subcutaneous Lenacapavir
The incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir compared with daily oral emtricitabine-tenofovir disoproxil fumarate.
Gilead Sciences’ Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...
GlobalData on MSN14d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.